CMS

designer491 Ardelyx (NASDAQ:ARDX) stock tumbled 20% Tuesday morning after the company said it has decided not to apply to include its drug Xphozah in the US Centers for Medicare and Medicaid Services’ Transitional Drug Add-on Payment Adjustment, or TDAPA, program for certain renal disease drugs. The biotech company said inContinue Reading